As Editor in Chief, Jeffrey Kanige oversees all editorial operations for The Deal. Most recently he has led efforts to develop more in-depth coverage of markets and debt financing.
A lawyer by training, Jeff has been a professional writer and editor for 27 years. He entered the industry as a stringer for the Courier-News, a daily newspaper in central New Jersey.
As a writer for New Jersey Reporter, a public policy journal based in Princeton, he won several awards for his coverage of state politics and government, and served as a political commentator and advisor for television stations in New Jersey and Philadelphia.
He has also covered the courts for Manhattan Lawyer, a unit of American Lawyer Media, worked as a reporter for the New Jersey Law Journal and was associate editor of the Law Journal and assistant managing editor for the New York Law Journal. Jeff has been with The Deal since its inception in 1999.
Winning the GOP presidential nod was too much for one man. So the presumptive nominee must have opted for an unusual form of self-help.
It's all over but the shouting. Only one question remains. Where will the president-elect be on Jan. 20 2017?
Assume that everything you thought you knew about politics is wrong. This time around, it's a reasonable assumption.
If by seismic we mean slow, grinding and ending with a tremor.
Democratic candidates Jim Webb, Lincoln Chafee or Martin O'Malley have yet to gain traction among Democratic primary voters. It's time to channel their inner Newt Gingrich.
The car business faces a shift down the road as the car culture changes.
Spanish oil company Repsol lost a huge chunk of its proven reserves in a dispute with Argentina over YPF, a South American subsidiary.
On Friday, the publisher of Time, Sports Illustrated, People and Fortune will set out on its own, as Time Warner completes its spinoff. And Time isn't the only media company splitting apart.
Billionaire Bill Ackman has never been reluctant to blaze trails. Now he's considering listing his offshore fund in London, a move that would free him from the whims of wimpy investors.
Jeff Immelt and Ian Read took different approaches in their quests to acquire big targets in France and England, but ended up in similar situations. General Electric's CEO started by reaching a friendly agreement with Alstom's board. When French politicians found out, they jumped in to save the company from the Americans. Pfizer's chief began by courting British government officials. And when AstraZeneca's directors received Read's $100 billion offer — the biggest ever for a U.K. target — they dismissed it as too low. Both deals could still get done. For now, though, political and cultural issues dominate the debates. The merits of the mergers are secondary.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.